Tuesday, December 5

    The aging process brings with it many challenges, including a decline in physical health, increased susceptibility to diseases, and the gradual wear and tear of vital organs. A significant contributor to these issues is the accumulation of senescent cells—cells that have essentially retired from their normal cycle of growth and division but continue to exert adverse effects on the body. While these cells play a beneficial role in tissue repair and injury prevention, their build-up can also lead to inflammation, tissue damage, and a range of age-associated conditions.

    Senolytics are a class of drugs that have emerged as a potential solution to this problem, targeting these nonfunctional cells for removal. As scientists work to understand how best to use synthetic senolytics like dasatinib and navitoclax, there’s a parallel interest in exploring natural alternatives. In this article, we’ll take a closer look at what senolytics are, how they work, and the role of both synthetic and natural compounds in the field.

    Understanding Cellular Senescence

    Cellular senescence is essentially a state of irreversible growth arrest. This occurs naturally as cells become damaged or reach the end of their replicative lifespan. Although this mechanism prevents damaged cells from proliferating uncontrollably—which could result in cancer—it has a downside. Senescent cells can secrete a range of harmful proteins that can lead to chronic inflammation, a common thread in many age-related diseases including arthritis, heart disease, and Alzheimer’s.

    Mechanisms of Senolytics

    Senolytics operate through various mechanisms to selectively induce apoptosis (programmed cell death) in senescent cells. One mechanism involves disrupting the survival pathways that these cells rely on, thereby making them more susceptible to natural cell death. This selective targeting is crucial because while the aim is to reduce the number of senescent cells, there is a need to avoid harming healthy, functional cells.

    Synthetic Senolytics: Leading the Way

    When discussing senolytics, it’s impossible not to mention drugs like dasatinib and navitoclax, which are commonly cited in scientific literature.


    Initially approved for treating certain types of leukemia, dasatinib has shown promise as a senolytic agent. Studies have reported its effectiveness in eliminating senescent cells, especially in combination with other senolytics like quercetin1.


    This is another drug that was originally developed for cancer treatment. Navitoclax works by inhibiting proteins that prevent apoptosis, thereby allowing senescent cells to undergo natural cell death2.

    Natural Senolytics: An Alternative Path

    While synthetic senolytics have been the cornerstone of most research, there’s a growing focus on natural compounds that may serve similar functions. Some of the most promising natural senolytics include:


    This flavonoid, which is abundantly found in strawberries and apples, has demonstrated significant senolytic properties. Fisetin not only targets senescent cells but also has antioxidant and anti-inflammatory properties that may contribute to its overall beneficial effects3.


    Present in foods like onions and green tea, quercetin is another flavonoid that has gained attention for its senolytic capabilities. Interestingly, quercetin is often more effective when used in conjunction with dasatinib, highlighting the potential for synergistic effects between synthetic and natural senolytics4.


    Derived from the turmeric root, curcumin is widely celebrated for its anti-inflammatory properties. Although still in the early stages of research, some studies suggest that curcumin could have senolytic potential as well5.

    The Next Steps: Clinical Trials and Research Directions

    The world of senolytics is still relatively new, but the potential impact on healthcare could be profound. Several phase II clinical trials are underway, aimed at understanding the long-term effects and safety of both synthetic and natural senolytics6. These trials will provide much-needed data that could spur the development of targeted therapies for a wide range of age-related diseases.

    Further Areas of Inquiry

    • Is there a potential for drug resistance in long-term senolytic therapy?
    • Can senolytics be effectively used as preventive treatment before the onset of age-related diseases?
    • What are the ethical considerations in the potential for senolytics to extend human lifespan?

    Final Thoughts

    The burgeoning field of senolytics offers a glimmer of hope in the quest to understand and mitigate the aging process. While synthetic compounds like dasatinib and navitoclax have been at the forefront, natural compounds such as fisetin, quercetin, and curcumin are also showing promise. As science continues to unravel the complexities of cellular senescence and its role in aging, senolytics stand as a promising approach in the fight against age-related diseases and the pursuit of healthier, more fulfilling lives.


    1. Dasatinib Plus Quercetin prevents and alleviates many senescence-associated phenotypes, Experimental Gerontology, 2021. ↩
    2. The BCL-2/BCL-XL Inhibitors, Navitoclax and ABT-737, are Senolytic, Cell Metabolism, 2018. ↩
    3. Fisetin is a senotherapeutic that extends health and lifespan, EBioMedicine, 2018. ↩
    4. Quercetin and Senescence, Frontiers in Physiology, 2016. ↩
    5. Curcumin and Cellular Senescence: A Review, Molecules, 2019. ↩
    6. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study, The Lancet, 2019. ↩
    FDA Compliance

    The information on this website has not been evaluated by the Food & Drug Administration or any other medical body. We do not aim to diagnose, treat, cure or prevent any illness or disease. Information is shared for educational purposes only. You must consult your doctor before acting on any content on this website, especially if you are pregnant, nursing, taking medication, or have a medical condition